BioNxt Solutions (BXT) AI Stock Analysis

BioNxt Solutions

(XETRA:BXT)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Improving asset baseThe increase in total assets during the trailing twelve months provides a modest improvement in the company’s resource base. While it does not resolve negative equity or solvency concerns, asset growth could support operations if paired with a credible path to revenue generation and better capital discipline.

Negative Factors

Revenue collapseRevenue has effectively disappeared from the reported business, falling from 372k in 2023 to zero in both 2025 and the trailing twelve months. Without meaningful sales, the company has little operating scale to absorb expenses, making recovery dependent on restoring commercial activity.

BioNxt Solutions (BXT) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 22.67M
Dividend Yield: ―
Average Volume (3M): 27.22K
Price to Earnings (P/E): -3.5
Beta (1Y): 0.61
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 25
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

BioNxt Solutions Business Overview & Revenue Model

Company Description

Headquartered in Vancouver, Canada, BioNxt Solutions Inc., established in 2017, operates as a bioscience company across Germany, Switzerland, Austria, Israel, and its home country. The firm focuses on developing innovative drug delivery systems, incl...

BioNxt Solutions Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:BXT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:LABS	49Neutral	CAD 27.77M	-5.60	-13.79%	―	-6.74%	43.54%
TSE:ATLE	42Neutral	CAD 41.96M	-0.76	-2099.75%	―	-100.00%	94.43%
TSE:AVCN	41Neutral	CAD 14.11M	-3.24	-108.44%	―	-0.23%	-142.54%
TSE:INNO	41Neutral	CAD 8.55M	-6.57	-19.37%	―	-19.20%	42.54%

* Healthcare Sector Average

Performance Comparison

DE:BXT and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:BXT	Bionxt Solutions Inc	0.19	-0.33	-63.37%
TSE:ATLE	Willow Biosciences	0.09	-0.07	-43.75%
TSE:LABS	Medipharm Labs (Otc)	0.07	-0.01	-13.33%
TSE:AVCN	Avicanna Inc	0.10	-0.16	-60.38%
TSE:INNO	Innocan Pharma Corporation	1.90	-16.10	-89.44%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

BioNxt Solutions AI Stock Analysis